New drug trial offers hope for advanced liver cancer patients
NCT ID NCT07297654
Summary
This study is testing whether the drug lenvatinib can help control advanced liver cancer in patients who aren't eligible for surgery or transplants. Fifty participants with moderately severe liver damage will take the oral medication daily until their cancer worsens or side effects become too severe. Researchers will track how long patients live without their cancer getting worse and monitor safety throughout the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.